Inspired by patients and driven by hope that our therapy will address the unmet need of serious and complex mitochondrial diseases
We are dedicated to rapidly advance life-changing therapies that address the unmet need of serious and complex mitochondrial diseases. We are the first company to develop a cell therapy approach to treat a broad range of indications generated by a mitochondrial dysfunction. Using our proprietary Mitochondrial Augmentation Therapy (MAT), designed to be a robust therapeutic platform combining personalized mitochondrial cell therapy and scalable manufacturing processes, we are advancing breakthrough therapies for patients with mitochondrial diseases ranging from ultra-rare to more common.
The technology behind Minovia was inspired by the endosymbiotic theory: around 1.5 billion years ago, mitochondria were bacterial cells that invaded a larger host cell and throughout evolution became an integral and essential energy-producing organelle for the cell.
After years of mitochondrial research my journey with Minovia began with a profound question: if we could harness the incredible power of mitochondria for therapeutic purposes, how many lives could be transformed?
Minovia was established in 2012 to answer this question and, having met the parents and patients of those suffering from rare and devastating mitochondrial diseases, the passion roared inside me.
Full of endeavor, my scientific curiosity transformed into a voracious desire to do something to help these patients, which is how the mitochondrial augmentation concept was conceived.
Now, we are on the edge of something remarkable.
We have a dedicated team of researchers working symbiotically with clinical and academic partners – combining our passion and ambition to firmly establish Mitochondrial Augmentation Therapy (MAT) as the answer for patients who suffer from mitochondrial diseases, in the hope that we can make a difference to their lives.
Minovia is determined to advance MAT for rare primary mitochondrial diseases, like Pearson Syndrome, Leigh Syndrome, KSS and MELAS and given that mitochondrial dysfunction is accumulated as we age, we believe that MAT has the potential to become a therapy that each and every one of us will need.
Mitochondria may be 1.5 billion years old but we’re only in the beginning of this exciting journey.
Welcome to Minovia.
We believe that bringing transformative therapies to patients requires collaborative spirit and joint efforts from many parties: patients, families and advocacy groups, scientists and academic institutions, clinicians and medical centers, regulators, and industry.
That is why we embrace cross-disciplinary collaborations with the world’s leading scientists, clinicians, hospitals, and pharmaceutical companies, in the journey to realize the full potential of Mitochondrial Augmentation Therapy (MAT) to make a meaningful impact on the lives of patients around the world.